This is not the most recent version of the article. View current version (8 FEB 2016)

Intervention Protocol

You have free access to this content

Antithrombin III for critically ill patients

  1. A Afshari,
  2. AM Møller,
  3. J Wetterslev

Editorial Group: Cochrane Anaesthesia Group

Published Online: 20 JUL 2005

DOI: 10.1002/14651858.CD005370


How to Cite

Afshari A, Møller AM, Wetterslev J. Antithrombin III for critically ill patients (Protocol). Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD005370. DOI: 10.1002/14651858.CD005370.

Author Information

*Dr Arash Afshari, Resident, Department of anaesthesiology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, Copenhagen, 2100 Ø, DENMARK. arriba_a@yahoo.dk.

Publication History

  1. Publication Status: Unchanged
  2. Published Online: 20 JUL 2005

SEARCH

This is not the most recent version of the article. View current version (08 FEB 2016)

References

Additional references

Alderson 2004
  • Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]. In: The Cochrane Library. The Cochrane Collaboration. Chichester: John Wiley & Sons, Ltd. 2004, Issue 1.
Angus 2001
  • Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Critical Care Medicine 2001;Jul;29(7):1303-10. [MEDLINE: 11445675].
Becker 2000
Bernard 2001
  • Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. The New England Journal of Medicine 2001;344(10):699-709. [MEDLINE: 11236773].
Egger 1997
Fourrier 2000
Hróbjartsson 2004
Larsson 2001
  • Larsson H, Åkerud P, Nordling K, Raub-Segall E, Claesson-Welsh L, Bjork I. A novel anti-angiogenic form of antithrombin with retained proteinase binding ability and heparin affinity. The Journal of Biological Chemistry 2001;276(15):11996-2002. [MEDLINE: 11278631].
Levi 2004
  • Levi M, de Jonge E, van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Annals of Medicine 2004;36:41-9.
Müllner 2004
  • Müllner M, Urbanek B, Havel C, Losert H, Waechter F, Gamper G. Vasopressors for shock. The Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD003709. DOI: 10.1002/14651858.CD003709.pub2.
Opal 2002
Opal 2003
Periti 2000
  • Periti P. Current treatment of sepsis and endotoxaemia. Expert opinion of Pharmacotherapy 2000;1(6):1203-17. [MEDLINE: 11249488].
Polderman 2004
Review Manager 4.2
  • The Cochrane Collaboration. Review Manager (RevMan). Oxford, England: The Cochrane Collaboration, 2004.
Rublee 2003
  • Rublee D, Opal SM, Schramm W, Keinecke HO, Knaub S. Quality of life effects of antithrombin III in sepsis survivors: results from the KyberSept trial. Critical Care 2002;Aug; 6(4):349-56. [MEDLINE: 12225612].
Warren 2001
Wiedermann 2002
Wiedermann 2004